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Transcriptomic alterations of MYC targets are associated with human cancers, including 
hepatocellular carcinoma (HCC). RNA binding proteins (RBPs), key regulators of RNA 
processing, can mediate cancer-associated transcriptomic changes often observed in HCC. In 
this study, we investigated the oncogenic role of the RBP Negative elongation factor E (NELFE) 
in HCC. NELFE mRNA is significantly elevated in HCC, which is attributed by increased gene 
copy number alterations. Moreover, increased NELFE gene copy is associated with poor 
survival. We show that oncogenic activation of NELFE promotes HCC progression by 
enhancing MYC signaling in two ways: 1) NELFE can directly interact with the 3’UTR of MYC 
target mRNAs to affect RNA stability or 2) through protein-protein interactions where NELFE 
modulates MYC binding to its target gene promoter regions to enhance transcription. Moreover, 
the overexpression of NELFE in MYC-induced HCC Trp53flox/flox;alb-cre mouse models 
enhanced HCC progression. We thus exploited this interplay by performing survival risk 
prediction analysis to develop a 20-NELFE dependent MYC target (NDMT) gene signature. This 
signature identified two distinctive subclasses associated with overall survival. In addition, 
independent cross-validation in four independent cohorts of more than 900 HCC samples 
demonstrate that the 20-NDMT signature is robust and predictive independently of clinical 
characteristics. In addition, high risk patients who have undergone transarterial 
chemoembolization (TACE) has a worse prognosis and increased recurrence. Together, our 
results suggest that oncogenic activation of NELFE supports a transcriptomic imbalance that 
promotes HCC progression.  
 
 
